Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A.
Toxicology letters October 1, 2018 Carolina Noble, Niels Bjerre Holm, Marie Mardal et al. 17 citations
Bromo-dragonfly, a potent and long-acting hallucinogen linked to severe vasoconstriction and fatal intoxications, was not metabolized in human liver microsomes, cytosol, or recombinant enzyme systems, unlike its analogue 2C-B-fly, which underwent monohydroxylation and N-acetylation via CYP2D6 and MAO-A. Bromo-dragonfly competitively inhibited monoamine oxidase A (MAO-A) with a Ki of 0.352 μM, and its IC50 suggested clinically relevant MAO-A inhibition, though further data are needed to assess its impact on serotonin levels in the body. Protein binding and pharmacokinetic parameters were also investigated.